NVIDIA and AWS collaborate to bring BioNeMo AI platform to the cloud

3D protein structure prediction with AlphaFold2, OpenFold, and ESMFold in NVIDIA’s BioNeMo. [NVIDIA]

Chipmaker NVIDIA and cloud behemoth AWS have been partnering for years, and now the two companies are announcing that NVIDIA’s drug discovery generative AI platform, BioNeMo, is now available on AWS. Additionally, plans are underway for BioNeMo to be offered on AWS on NVIDIA DGX Cloud.

The alliance was announced at the AWS re:Invent event. Startups including Evozyne, Etcembly and Alchemab are early AWS users using BioNeMo for generative AI-accelerated drug discovery and development.

Evozyne focuses on creating novel proteins for therapeutic development, Etcembly is building a large machine learning database for immunology and TCR immunotherapies, and Alchemab specializes in identifying protective antibodies for hard-to-treat diseases.

Last week, NVIDIA announced a collaboration with Genentech with BioNeMo also playing a ke…

Read more
  • 0

Quantum leaps in drug discovery? NobleAI joins forces with Microsoft while King’s College London aligns with Kvantify

[Production Perig/Adobe Stock]

The word “revolutionize” gets thrown around a lot in describing the potential of emerging technologies. But quantum computing could make good on the promise to disrupt healthcare applications ranging from drug discovery to medical imaging. Theoretically, a quantum computer with 300 quantum bits (qubits) could crunch more calculations in an instant than there are atoms in the visible universe. Because qubits can exist in multiple states at once, quantum computers can bring powerful parallel processing to fields where exploring a vast solution space is required, including drug discovery and material science.

It’s no wonder that the computing branch, which remains in its infancy, is attracting a growing amount of attention as it inches towards practical applicability. In May, Insilico Medicine said it was exploring the use of quantum computing and generative AI to help ide…

Read more
  • 0

Microsoft goes all in on Azure Quantum to accelerate scientific discovery

[Peter Jurik/Adobe Stock]

In the rapidly evolving landscape of quantum computing, Microsoft is pushing the boundaries with its Azure Quantum platform. As Microsoft CEO Satya Nadella recently announced, “Our goal is to compress the next 250 years of chemistry and material science progress into the next 25,” Nadella said. The executive also noted that, thanks to recent advances in quantum computing, “we’re closer than ever to the promise of a scalable quantum machine capable of solving some of the world’s most intractable problems.”

To accelerate this vision, Microsoft’s Azure Quantum introduces capabilities to expedite scientific discovery. Azure Quantum Elements merges high-performance computing, AI and quantum computing on Microsoft Azure. This combination accelerates quantum chemistry simulations and widens the search space for new materials. Azure Quantum Elements taps AI models traine…

Read more
  • 0

Solving three major IT challenges of pharmaceutical high-performance computing

Photo by Manuel Geissinger from Pexels

Over the past two decades, high-performance computing (HPC) has become widely used throughout drug discovery and development. Significant advances in HPC processing power in the early 2000s made it viable for tasks like reverse-engineering models of human disease progression and drug response or processing vast amounts of data from sources like the Human Genome Project. An article published in Expert Opinion on Drug Discovery claimed, “we can safely state that it would not be possible to process all the information available in the chemical databases of potential drug compounds, either accurately or quickly without HPC, since the required computational power is huge.”

One aspect of this shift that often goes overlooked is the new demands that HPC workloads place on IT and network operations (NetOps) teams at the organizations that use them. High-performance computing re…

Read more
  • 0